Unleashing Synergy:

Oncolytic Virotherapy and mRNA Vaccines
Unite in the Battle Against Cancer

Virogin Biotech is a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer.

We have developed two platforms: (1) innovative HSV-1 based oncolytic virus and (2) mRNA-based (including self-amplifying RNA/saRNA) therapeutics, aiming to elicit robust and durable anti-tumor immune response against solid tumors.

Both platforms exhibit a high degree of complementarity via a mechanism of Heterologous Prime-Boost. Yet each platform has ‘plug-to-play’ features to independently develop novel therapies against cancer & other indications. This combination approach presents a unique opportunity to elevate tumor vaccine immunotherapy to an unprecedented level.

Our oncolytic HSV-1 platform has two candidates in clinical trials, with our most advanced asset in Phase 2. Candidates from our mRNA platform have also completed preclinical proof of concept.


Join our journey and be part of our team! Bring your passion and determination to make a difference in solving one of the world’s biggest challenges—a future without cancer.